Date of Award


Document Type




First Reader

Dr. Joseph Bradshaw

Second Reader

Dr. B. Allyson Phillips

Third Reader

Dr. Johnny Wink


Photodynamic therapy (PDT) is a relatively new treatment option in medicine including treating some types of cancers. PDT utilizes light to activate small molecules for treatment. Some of these molecules used as PDT agents are porphyrin derivatives. While PDT is currently being used in the fight against cancer, it has several limitations and is currently being used in conjunction with chemotherapy and/or radiation in order to be effective. This research focused on synthesizing a new zinc (II) porphyrin and incorporating a fluorescent sulfocycline and testing the compound on the MB 231 breast cancer cell line.

Once the metallated porphyrin was synthesized and purified, IR, UV-vis, fluorescence, and NMR spectroscopies were run to characterize the compound. Once this data was collected, the compound was tested on the MB231 cell line. The MB231 cell line is also referred to as triple negative breast cancer cells. After cells were treated with the metallated porphyrin an MTI assay was run to look at cell viability in both light and dark conditions.

Along with the testing of the synthesized metallated porphyrin, research was done on how patient attitude has been shown to effect patient outcome. While looking at this, cancer patients were focused on. In order to increase the number of available cases, other diseases were looked at as well.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.